Novo Nordisk’s oral semaglutide demonstrates potential to
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged…
Novo Nordisk’s zenagamtide shows 14.6% weight-loss in mid-stage diabetes study, ETPharma
Plainsboro: Novo Nordisk’s next-generation weight-loss candidate, zenagamtide has delivered an average weight-loss of up to 14.6 per cent…
Abbott and Novo Nordisk partner to launch Extensior for diabetes care in India
India’s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a…